BioCentury | Jan 25, 2019
Politics, Policy & Law

101 problems with patent eligibility

The U.S. diagnostics industry is being strangled, and other life science inventions are being hobbled by, ill-conceived and contradictory patent policies. The USPTO director has signaled he wants to help, but only Congress has the...
BC Week In Review | Aug 1, 2016
Company News

Sequenom, LabCorp deal

LabCorp will acquire fellow diagnostics company Sequenom for $2.40 per share in cash, or about $371 million including Sequenom’s net debt. The price is a 182% premium to Sequenom’s close of $0.85 on July 26,...
BC Extra | Jul 27, 2016
Company News

LabCorp acquiring Sequenom

Diagnostics company Laboratory Corp. of America Holdings (NYSE:LH) is acquiring Sequenom Inc. (NASDAQ:SQNM) for $2.40 per share, or about $371 million including Sequenom's net debt. The price is a 182% premium to Sequenom's close of...
BC Week In Review | Jul 11, 2016
Company News

Natera, Sequenom, Thermo Fisher, Roche diagnostic news

The U.S. Supreme Court declined to review a lower court decision invalidating U.S. Patent No. 6,258,540 covering prenatal diagnosis with nucleic acid analysis used in Sequenom’s MaterniT21 Plus laboratory-developed test. Sequenom had asked SCOTUS to...
BC Extra | Jul 7, 2016
Politics & Policy

CAFC vacates decision that invalidated a process patent

The U.S. Court of Appeals for the Federal Circuit found that a patent covering a process for preserving hepatocytes by multiple freeze-thaw cycles was not directed to a patent-ineligible law of nature, vacating a lower...
BC Extra | Jun 28, 2016
Politics & Policy

Supreme Court denies Sequenom petition

In a blow to the diagnostics industry, the U.S. Supreme Court declined to review a lower court's decision that had invalidated a patent owned by Sequenom Inc. (NASDAQ:SQNM) covering a prenatal diagnostic test. The company...
BC Extra | Apr 28, 2016
Company News

Management tracks

Cancer company ImmunoGen Inc. (NASDAQ:IMGN) hired Mark Enyedy as president, CEO and a director, effective May 16. Enyedy was EVP and head of corporate development at Shire plc (LSE:SHP; NASDAQ:SHPG). He replaces Daniel Junius, who...
BioCentury | Apr 4, 2016
Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Yrs cash pre-cut Cash date 12-mo op loss ended 12/31 1/7/16 Sequenom Inc. (NASDAQ:SQNM) 20% to 390 $76.2 9.65 12/31/15 $7.9 Sequenom restructured to focus on women's health...
BC Week In Review | Apr 4, 2016
Company News

Sequenom, Anthem sales and marketing update

Anthem Blue Cross and Blue Shield of Connecticut, Maine and New Hampshire will cover Sequenom’s noninvasive prenatal tests for high- and average-risk pregnancies. The company’s products include MaterniT21 Plus LDT, which detects trisomies along with...
BC Week In Review | Jan 18, 2016
Company News

Sequenom diagnostic, supply/service news

Sequenom said it will reduce headcount by about 110 (20%) to about 390 and restructure to focus on women’s health, including R&D programs for tests serving obstetricians, gynecologists and maternal fetal medicine specialists, and expanding...
Items per page:
1 - 10 of 449
BioCentury | Jan 25, 2019
Politics, Policy & Law

101 problems with patent eligibility

The U.S. diagnostics industry is being strangled, and other life science inventions are being hobbled by, ill-conceived and contradictory patent policies. The USPTO director has signaled he wants to help, but only Congress has the...
BC Week In Review | Aug 1, 2016
Company News

Sequenom, LabCorp deal

LabCorp will acquire fellow diagnostics company Sequenom for $2.40 per share in cash, or about $371 million including Sequenom’s net debt. The price is a 182% premium to Sequenom’s close of $0.85 on July 26,...
BC Extra | Jul 27, 2016
Company News

LabCorp acquiring Sequenom

Diagnostics company Laboratory Corp. of America Holdings (NYSE:LH) is acquiring Sequenom Inc. (NASDAQ:SQNM) for $2.40 per share, or about $371 million including Sequenom's net debt. The price is a 182% premium to Sequenom's close of...
BC Week In Review | Jul 11, 2016
Company News

Natera, Sequenom, Thermo Fisher, Roche diagnostic news

The U.S. Supreme Court declined to review a lower court decision invalidating U.S. Patent No. 6,258,540 covering prenatal diagnosis with nucleic acid analysis used in Sequenom’s MaterniT21 Plus laboratory-developed test. Sequenom had asked SCOTUS to...
BC Extra | Jul 7, 2016
Politics & Policy

CAFC vacates decision that invalidated a process patent

The U.S. Court of Appeals for the Federal Circuit found that a patent covering a process for preserving hepatocytes by multiple freeze-thaw cycles was not directed to a patent-ineligible law of nature, vacating a lower...
BC Extra | Jun 28, 2016
Politics & Policy

Supreme Court denies Sequenom petition

In a blow to the diagnostics industry, the U.S. Supreme Court declined to review a lower court's decision that had invalidated a patent owned by Sequenom Inc. (NASDAQ:SQNM) covering a prenatal diagnostic test. The company...
BC Extra | Apr 28, 2016
Company News

Management tracks

Cancer company ImmunoGen Inc. (NASDAQ:IMGN) hired Mark Enyedy as president, CEO and a director, effective May 16. Enyedy was EVP and head of corporate development at Shire plc (LSE:SHP; NASDAQ:SHPG). He replaces Daniel Junius, who...
BioCentury | Apr 4, 2016
Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Yrs cash pre-cut Cash date 12-mo op loss ended 12/31 1/7/16 Sequenom Inc. (NASDAQ:SQNM) 20% to 390 $76.2 9.65 12/31/15 $7.9 Sequenom restructured to focus on women's health...
BC Week In Review | Apr 4, 2016
Company News

Sequenom, Anthem sales and marketing update

Anthem Blue Cross and Blue Shield of Connecticut, Maine and New Hampshire will cover Sequenom’s noninvasive prenatal tests for high- and average-risk pregnancies. The company’s products include MaterniT21 Plus LDT, which detects trisomies along with...
BC Week In Review | Jan 18, 2016
Company News

Sequenom diagnostic, supply/service news

Sequenom said it will reduce headcount by about 110 (20%) to about 390 and restructure to focus on women’s health, including R&D programs for tests serving obstetricians, gynecologists and maternal fetal medicine specialists, and expanding...
Items per page:
1 - 10 of 449